Exhaustion of T cells in HIV-1 and HIV-2 infection

Exhaustion of T cells in HIV-1 and HIV-2 infection - T cell Exhaustion in HIV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43390

Enrollment

154

Registered

2016-05-04

Start date

2016-05-26

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS HIV infection

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age >18 years 2. Confirmed HIV-1 or HIV-2 infection 3. Fit description of study groups as outlined above

Exclusion criteria

Exclusion criteria: 1. Inability to donate 50 ml of blood 2. Pregnancy or breastfeeding 3. Major comorbidities

Design outcomes

Primary

Measure	Time frame
This is a discovery study aiming to examine exhaustion of HIV-specific CD8+ and CD4+ T cells in HIV-1 and HIV-2 infection and the role of epigenetic modifications in the exhaustion and function of these cells. The main study parameters are differences in a) phenotype (differentiation, activation, inhibitory receptor expression and transcription factors), b) effector functions (cytokine production, cytotoxicity), c) survival and d) proliferation of HIV-specific T cells; e) differentiation and activation phenotypes, and function of immune subpopulations (i.e. CD4+ and CD8+ T cells, B cells, NK cells, macrophages and DC). These differences will be measured directly ex vivo and after in vitro treatment with inhibitors of different classes of epigenetic modifiers	—

Measure

Time frame

This is a discovery study aiming to examine exhaustion of HIV-specific CD8+ and CD4+ T cells in HIV-1 and HIV-2 infection and the role of epigenetic modifications in the exhaustion and function of these cells. The main study parameters are differences in a) phenotype (differentiation, activation, inhibitory receptor expression and transcription factors), b) effector functions (cytokine production, cytotoxicity), c) survival and d) proliferation of HIV-specific T cells; e) differentiation and activation phenotypes, and function of immune subpopulations (i.e. CD4+ and CD8+ T cells, B cells, NK cells, macrophages and DC). These differences will be measured directly ex vivo and after in vitro treatment with inhibitors of different classes of epigenetic modifiers

—

Countries

Netherlands

Outcome results